New-generation cardiac ablation technology expands treatment options for atrial fibrillation patients, offering a non-thermal approach to improve safety and procedural efficiency
The drug currently approved for chronic kidney disease (CKD) associated with type 2 diabetes, may benefit a much broader group of patients than previously recognized
New platform integrates advanced cardiac mapping and ablation workflow, offering a novel treatment option for AFib patients at risk of stroke and heart failure
POSEIDON is among the largest global datasets to quantify this residual inflammatory burden
Pan-India multidisciplinary program aims to improve coordinated care for patients with chronic kidney disease and heart failure
Offers a non-surgical treatment option for tricuspid regurgitation, a commonly underdiagnosed heart valve disorder linked to heart failure
The company has supported the initiative since its inception, contributing to screening efforts in around 120 countries
American College of Cardiology and Korean Society of Cardiology convene global experts to address rising cardiometabolic burden
The new single-pill therapy combines cilnidipine, telmisartan and metoprolol, bringing together three established antihypertensive agents with complementary mechanisms
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
Subscribe To Our Newsletter & Stay Updated
